黑石集团与德州太平洋集团将收购豪洛捷，每股收购价最高 79 美元。 ...

MARLBOROUGH, Mass. & NEW YORK & SAN FRANCISCO & FORT WORTH, Texas--(BUSINESS WIRE)---- $HOLX #aquisition--Hologic to be Acquired by Blackstone and TPG for up to $79 per Share. ...

Core Insights - U.S. stock markets are experiencing a midday rally driven by easing concerns over regional bank stability, de-escalation in U.S.-China trade tensions, and strong performances from tech companies [1][9] Major Market Indexes Performance - The S&P 500 Index (SPX) has increased by approximately 0.7% to 1.0%, nearing its all-time high [2] - The Nasdaq Composite Index (IXIC) is leading with gains between 0.8% and 1.4%, fueled by optimism in AI sectors and strong tech earnings expectations [2] - The Dow Jones Industrial Average (DJIA) has risen around 0.5% to 0.8%, adding over 200 points, indicating renewed investor confidence [2] - The Cboe Volatility Index (VIX) has slightly dipped but remains above 20, indicating some caution among institutional investors [2] Upcoming Market Events - The week of October 20-24, 2025, features a busy financial calendar with significant corporate earnings reports expected from major companies like Coca-Cola, Tesla, and Procter & Gamble [3] - Other notable companies reporting include Netflix, IBM, Intel, General Motors, Ford, Lockheed Martin, and RTX [3] - Regional banks such as Zions Bancorp and Western Alliance Bancorp are also set to report, with a focus on loan quality [3] Economic Indicators - The ongoing U.S. government shutdown is affecting the data landscape, but the September Consumer Price Index (CPI) report is anticipated on October 24, providing insights into inflation trends [4] - Key economic indicators to monitor include S&P Global flash PMIs and existing home sales [4] Major Stock News and Developments - Apple (AAPL) shares have surged over 4%, reaching a new all-time high due to strong demand for the iPhone 17 series [5] - Amazon (AMZN) shares have recovered after an initial dip, despite an AWS outage affecting several online services [6] - Smaller and mid-sized bank stocks are recovering after previous losses, while Moderna (MRNA) shares are up approximately 7% following positive vaccine data [7] - Beyond Meat (BYND) has soared over 68% due to a short squeeze, and Cleveland-Cliffs (CLF) has increased by over 24% after strong earnings [7] - Kering (KER) rose 3.6% after agreeing to sell its Kering Beaute division to L'Oreal for €4 billion [7]

Shares of Hologic Inc (NASDAQ:HOLX) are up 2.4% to trade at $71.51 at last glance, earlier tapping $73.09 their highest level since early January. Driving the upbeat price action is a Bloomberg report that Blackstone (BX) and TPG (TPG) are looking to buy the medtech giant for $17 billion. HOLX is still stuck below its year-to-date breakeven level, but has now broken above recent overhead pressure at $70. Today's outperformance has the shares eyeing a fifth-straight win, a bounce that originated at their 100 ...

Key Takeaways HOLX's Q4 fiscal 2025 earnings due Nov. 3; EPS estimated at $1.10 ( 8.9% YoY), revenues at $1.03B ( 4.7%).Hologic's Diagnostics unit bears the brunt of macro pressures, limiting Q4 growth potential.HOLX's Breast Health and GYN Surgical divisions show modest gains, but overall growth remains constrained.Hologic (HOLX) is set to release fourth-quarter fiscal 2025 results on Nov. 3, after the closing bell.The Zacks Consensus Estimate for fiscal fourth-quarter earnings per share (EPS) suggests an ...

Core Viewpoint - Hologic's stock performance has been mixed, with a recent increase but a decline over the past month, and upcoming earnings are anticipated to show growth in earnings per share and revenue [1][2][3]. Company Performance - Hologic closed at $68.50, reflecting a +2.24% change from the previous day, outperforming the S&P 500, which fell by 0.63% [1]. - Over the last month, Hologic's shares decreased by 1.76%, while the Medical sector gained 3.09% and the S&P 500 increased by 0.92% [1]. Upcoming Earnings - The earnings report is expected on November 3, 2025, with projected earnings of $1.1 per share, indicating a year-over-year growth of 8.91% [2]. - The Zacks Consensus Estimate for revenue is $1.03 billion, representing a 4.67% increase from the previous year [2]. Full Year Estimates - For the full year, analysts expect earnings of $4.24 per share and revenue of $4.08 billion, reflecting changes of +3.92% and 0% respectively from last year [3]. - Recent changes in analyst estimates are crucial as they often indicate shifts in near-term business trends [3]. Analyst Ratings - Hologic currently holds a Zacks Rank of 4 (Sell), with a recent 0.11% decrease in the Zacks Consensus EPS estimate over the last 30 days [5]. - The Zacks Rank system has a strong track record, with stocks rated 1 producing an average annual return of +25% since 1988 [5]. Valuation Metrics - Hologic has a Forward P/E ratio of 14.96, which is lower than the industry average of 23.97 [6]. - The company has a PEG ratio of 2.3, compared to the industry average PEG ratio of 2.54 [6]. Industry Context - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7]. - Strong industry rankings correlate with stock performance, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7].

Hologic (NASDAQ:HOLX) rose 2% in premarket trading after a report about financing for a potential takeover by Blackstone (BX) and TPG Inc. (TPG). Direct lenders are preparing a $9 billion debt financing package as they attempt to compete with banks to ...

With a market cap of $14.7 billion, Hologic, Inc. (HOLX) is a Massachusetts-based medical technology company specializing in women's health. Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical devices. Its core business segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. HOLX is all geared up for its fiscal Q4 2025 results after the market closes on Wednesday, Nov. 3. Before this event, analysts project this company to report ...

Core Viewpoint - Hologic (HOLX) has been trending in stock searches, with a recent performance of +2.7% over the past month, outperforming the S&P 500's +1.1% and the Zacks Medical - Instruments industry's -6.2% [1] Earnings Estimates - For the current quarter, Hologic is expected to report earnings of $1.10 per share, reflecting an increase of +8.9% year-over-year, although the Zacks Consensus Estimate has decreased by -0.3% in the last 30 days [4] - The consensus earnings estimate for the current fiscal year is $4.24, indicating a +3.9% change from the previous year, with a slight decrease of -0.1% over the last month [4] - For the next fiscal year, the consensus estimate is $4.48, showing a +5.6% increase from the prior year, with no change in the estimate over the past month [5] Revenue Growth - Hologic's consensus sales estimate for the current quarter is $1.03 billion, representing a year-over-year increase of +4.7% [10] - The sales estimates for the current and next fiscal years are $4.08 billion and $4.26 billion, indicating changes of +1.4% and +4.3%, respectively [10] Recent Performance and Surprise History - In the last reported quarter, Hologic achieved revenues of $1.02 billion, a +1.2% increase year-over-year, and an EPS of $1.08, compared to $1.06 a year ago [11] - The company surpassed consensus EPS estimates three times and revenue estimates three times over the last four quarters [12] Valuation - Hologic is graded B in the Zacks Value Style Score, suggesting it is trading at a discount compared to its peers [16]

Key Takeaways HOLX positions its GYN Surgical segment for strong growth with minimally invasive fibroid solutions.International efforts help Hologic drive consistent growth in minimally invasive surgical products.Gynesonics' acquisition strengthens Hologic's ability to treat mid-sized fibroids.Hologic (HOLX) continues to experience strong momentum across its GYN Surgical portfolio, underscoring the increasing global focus on women’s health. The company’s investments in commercial and market access capabilit ...